Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase

Prostaglandins and Other Lipid Mediators

Volumn 92, Issue 1-4, 2010, Pages 54-61

  Titos, Esther ^a,b   Ferré, Natàlia ^a   Lozano, Juan José ^b   Horrillo, Raquel ^a   López Parra, Marta ^a   Arroyo, Vicente ^a,b   Clària, Joan ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

5 Lipoxygenase; Knockout mice; Lipid metabolism

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE LYASE; ARACHIDONATE 5 LIPOXYGENASE; CARBON TETRACHLORIDE; CCAAT ENHANCER BINDING PROTEIN; ELONGATION FACTOR; ELONGATION OF VERY LONG CHAIN FATTY ACID 6; FATTY ACID SYNTHASE; LIPIN 1; PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; HEPATITIS; LIPID METABOLISM; LIVER INJURY; LIVER PROTECTION; MALE; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RISK FACTOR;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BODY WEIGHT; CARBOHYDRATE METABOLISM; GENE DELETION; INFLAMMATION; LIPID METABOLISM; LIVER; LIVER DISEASES; MALE; MICE; ORGAN SIZE;

EID: 77952322894     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.03.001     Document Type: Article

References (31)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983) 568-575
2. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
3. 4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286 (1980) 264-265
4. Dahlen S.E., Hedqvist P., Hammarstrom S., et al. Leukotrienes are potent constrictors of human bronchi. Nature 288 (1980) 484-486
5. Romano M., and Clària J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 17 (2003) 1986-1995
6. Radmark O., Werz O., Steinhilber D., et al. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 32 (2007) 332-341
7. Hagmann W., Kaiser I., and Jakschik B.A. The sensitized liver represents a rich source of endogenous leukotrienes. Hepatology 13 (1991) 482-488
8. Titos E., Clària J., Bataller R., et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 119 (2000) 794-805
9. Titos E., Clària J., Planagumà A., et al. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. J Leukoc Biol 78 (2005) 871-878
10. Titos E., Clària J., Planagumà A., et al. Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB J 17 (2003) 1745-1747
11. Horrillo R., Planagumà A., González-Périz A., et al. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J Pharmacol Exp Ther 323 (2007) 778-786
12. El-Swefy S., and Hassanen S.I. Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats. Ann Hepatol 8 (2009) 41-49
13. López-Parra M., Titos E., Horrillo R., et al. Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. J Lipid Res 49 (2008) 2513-2523
14. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
15. Kaaman M., Ryden M., Axelsson T., et al. ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance. Int J Obes (Lond) 30 (2006) 447-452
16. Siegers C.P., Reichl W., and Younes M. Sex differences in the susceptibility of rats to carbon tetrachloride-alcohol-induced liver injury. Agents Actions 14 (1984) 121-123
17. Irizarry R.A., Hobbs B., Collin F., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2003) 249-264
18. Smyth G.K. Limma: linear models for microarray data. In: Gentleman R., Carey V., Dudoit S., Irizarry R., and Huber W. (Eds). Bioinformatics and computational biology solutions using R and bioconductor. 2005 ed. (2009), Springer, New York 397-420
19. Long Y.C., and Zierath J.R. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116 (2006) 1776-1783
20. Daval M., Foufelle F., and Ferre P. Functions of AMP-activated protein kinase in adipose tissue. J Physiol 574 (2006) 55-62
21. Reue K., and Dwyer J.R. Lipin proteins and metabolic homeostasis. J Lipid Res 50 (2009) S109-S114
22. Martínez-Clemente M., Ferré N., González-Périz A., et al. 5-Lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology 51 (2010) 817-827
23. Horrillo R., González-Périz A., Martínez-Clemente M., et al. 5-Lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol 184 (2010) 3978-3987
24. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
25. Sanyal A.J. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 46-53
26. Zhao L., Moos M.P., Grabner R., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10 (2004) 966-973
27. Back M., Sultan A., Ovchinnikova O., and Hansson G.K. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 100 (2007) 946-949
28. Mehrabian M., Allayee H., Wong J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91 (2002) 120-126
29. Mehrabian M., Allayee H., Stockton J., et al. Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet 37 (2005) 1224-1233
30. Celotti F., and Durand T. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Other Lipid Mediat 71 (2003) 147-162
31. Whittle B.J., Varga C., Berko A., et al. Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol 153 (2008) 983-991